What are the risks of investing in QURE?
uniQure N.V. focuses on clinical-stage gene therapy development, exposing investors to extreme binary research and regulatory risk factors. Major vulnerabilities include the high probability of clinical trial setbacks or adverse safety findings for its complex pipeline candidates targeting conditions like Huntington's disease, alongside rigorous FDA and European regulatory approval hurdles. Additional threats comprise high research and development cash burn rates, lack of commercial product revenue streams, and heavy reliance on external equity financing leading to dilution.
Related FAQs
uniQure N.V. (NASDAQ: QURE) represents a high-risk, high-reward biotechnology investment focused primarily on advanced gene therapies.
uniQure has successfully secured landmark regulatory validation, including historic United States Food and Drug Administration approval for its breakthrough gene therapy treatment targeting adults with severe hemophilia B.
Value-Added Tax (VAT), which is widely utilized across European and international tax systems to tax goods and services at each stage of the supply chain, does not exist at the federal level in the United States and is instead replaced by state and l...
Equity research analysts tracking uniQure N.V. (NASDAQ: QURE) generally issue favorable buy or hold recommendations, reflecting institutional optimism surrounding its advanced gene therapy pipeline targeting severe genetic disorders.
Wall Street equity analysts tracking uniQure N.V. (NASDAQ: QURE) maintain an optimistic outlook, with consensus 12-month average price targets clustered around $59.17 to $69.18, and upper forecasts scaling up to $95.00.
uniQure N.V.
Hut 8 has experienced variable profitability, which is characteristic of major digital asset mining and high-performance computing infrastructure enterprises operating in cyclical markets.
Yes, the second term of President Donald Trump has made increased fossil fuel production a central focus [1.6.1].
UniQure N.V. faced corporate and scientific scrutiny following clinical trial safety holds and unexpected adverse event reports associated with its gene therapy pipeline candidates.
Institutional equity research analyst consensus price targets for uniQure N.V. (NASDAQ: QURE) average approximately $68.11, with high-end biotech institutional projections reaching up to $96.23 and conservative baseline estimates near $46.59.
uniQure N.V. (QURE) operates as a clinical-stage gene therapy enterprise pioneering transformative adeno-associated virus-based treatments for severe genetic and hereditary disorders.
uniQure N.V. is not a United States corporation, but rather a Dutch biotechnology enterprise headquartered in Amsterdam, Netherlands, with major corporate and research operations based in Lexington, Massachusetts.
uniQure N.V. navigated critical clinical development and regulatory milestones as a pioneer in human gene therapy.
uniQure N.V. (NASDAQ: QURE) trades on the NASDAQ exchange at $15.22 per share, maintaining a market capitalization of roughly $1.15 billion.
United Bankshares, Inc. is a major regional bank holding company operating extensively across the Mid-Atlantic and Southeastern regions of the United States, providing a full suite of commercial and retail banking services.
uniQure N.V. (QURE) operates as a clinical-stage biopharmaceutical pioneer focusing on gene therapy treatments for severe genetic, metabolic, and central nervous system disorders.
Folk music icon and legendary singer-songwriter Woody Guthrie famously battled Huntington's disease, a devastating hereditary neurodegenerative disorder, spending his final years hospitalized before passing away from complications related to the cond...
uniQure N.V. is entering a transformative period centered heavily around regulatory milestones and clinical advancements for its advanced gene therapy pipeline, particularly its lead investigational treatment AMT-130 for Huntington's disease.
Regulatory scrutiny and clinical developments involving the U.S.
UniQure is currently in a pivotal stage as it prepares for a Biologics License Application (BLA) submission for its treatment candidate AMT-130, following alignment with the FDA on an accelerated approval pathway.
uniQure N.V. is a pioneer in the competitive biotechnology sector specializing in clinical-stage and commercial gene therapies for rare genetic diseases, hemophilia, and central nervous system disorders.
uniQure N.V.